IMPA2 (inositol monophosphatase 2) is a phosphatase that dephosphorylates myo-inositol monophosphates and related substrates to regulate the phosphatidylinositol signaling cycle 1. The enzyme is inhibited by lithium at therapeutically relevant concentrations, implicating IMPA2 as a pharmacological target for lithium's mood-stabilizing effects 23. Genetically, IMPA2 variants have been associated with febrile seizures susceptibility on chromosome 18.2 4, and multiple studies suggest links to bipolar disorder susceptibility, with evidence for altered gene expression in affected individuals 526. Notably, IMPA2 expression correlates negatively with intracellular calcium levels in bipolar patients, suggesting involvement in calcium homeostasis dysregulation 5. Beyond neuropsychiatric disease, IMPA2 functions as an oncogene in cervical and basal-like breast cancers. IMPA2 silencing inhibits tumor proliferation and promotes paclitaxel sensitivity in cervical cancer through p53-mediated regulation 78. In breast cancer, IMPA2 upregulation promotes the myo-inositol-phosphatidylinositol cycle, elevating intracellular calcium and activating NFAT1, creating a positive feedback loop with MYC that drives aggressive tumor progression 9.